Premium
Increased circulating levels of thrombin‐activatable fibrinolysis inhibitor in lung cancer patients
Author(s) -
Hataji Osamu,
Taguchi Osamu,
Gabazza Esteban Cesar,
Yuda Hisamichi,
D'AlessandroGabazza C.N.,
Fujimoto Hajime,
Nishii Yoichi,
Hayashi Tatsuya,
Suzuki Koji,
Adachi Yukihiko
Publication year - 2004
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20079
Subject(s) - fibrinolysis , lung cancer , medicine , cancer , thrombin , adenocarcinoma , cancer research , small cell carcinoma , chemotherapy , pathology , gastroenterology , immunology , oncology , platelet
Impairment of fibrinolytic function plays an important role in the mechanism of thrombotic disorders in cancer patients. This study assessed the circulating level of thrombin‐activatable fibrinolysis inhibitor in patients with lung cancer and its expression by several lung cancer cell lines. The plasma concentrations of thrombin‐activatable fibrinolysis inhibitor were significantly increased in lung cancer patients compared to healthy subjects. The concentration of thrombin‐activatable fibrinolysis inhibitor was particularly higher in patients with small cell carcinoma compared to those with adenocarcinoma or squamous cell carcinoma, and in cancer patients that responded to chemotherapy compared to non‐responders. In vitro studies showed more expression of thrombin‐activatable fibrinolysis inhibitor in small cell carcinoma than in adenocarcinoma cell lines and more expression in lung cancer cell lines sensitive to anti‐cancer agents than in resistant cell lines. This study suggests that thrombin‐activatable fibrinolysis inhibitor, in part secreted from lung cancer cells, may play a role in the pathogenesis of thrombotic disorders in lung cancer patients. Am. J. Hematol. 76:214–219, 2004. © 2004 Wiley‐Liss, Inc.